Time-resolved studies define the nature of toxic IAPP intermediates, providing insight for anti-amyloidosis therapeutics

  1. Andisheh Abedini
  2. Annette Plesner
  3. Ping Cao
  4. Zachary Ridgway
  5. Jinghua Zhang
  6. Ling-Hsien Tu
  7. Chris T Middleton
  8. Brian Chao
  9. Daniel J Sartori
  10. Fanling Meng
  11. Hui Wang
  12. Amy G Wong
  13. Martin T Zanni
  14. C Bruce Verchere
  15. Daniel P Raleigh  Is a corresponding author
  16. Ann Marie Schmidt  Is a corresponding author
  1. New York University School of Medicine, United States
  2. Novo Nordisk, Denmark
  3. Stony Brook University, United States
  4. PhaseTech Spectroscopy, Inc., United States
  5. University of Wisconsin-Madison, United States
  6. University of British Columbia, Canada

Abstract

Islet amyloidosis by IAPP contributes to pancreatic β-cell death in diabetes, but the nature of toxic IAPP species remains elusive. Using concurrent time-resolved biophysical and biological measurements, we define the toxic species produced during IAPP amyloid formation and link their properties to induction of rat INS-1 β-cell and murine islet toxicity. These globally flexible, low order oligomers upregulate pro-inflammatory markers and induce reactive oxygen species. They do not bind 1-anilnonaphthalene-8-sulphonic acid and lack extensive β-sheet structure. Aromatic interactions modulate, but are not required for toxicity. Not all IAPP oligomers are toxic; toxicity depends on their partially structured conformational states. Some anti-amyloid agents paradoxically prolong cytotoxicity by prolonging the lifetime of the toxic species. The data highlight the distinguishing properties of toxic IAPP oligomers and the common features that they share with toxic species reported for other amyloidogenic polypeptides, providing information for rational drug design to treat IAPP induced β-cell death.

Article and author information

Author details

  1. Andisheh Abedini

    Diabetes Research Program, Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, New York University School of Medicine, New York, United States
    Competing interests
    The authors declare that no competing interests exist.
  2. Annette Plesner

    Novo Nordisk, Bagsværd, Denmark
    Competing interests
    The authors declare that no competing interests exist.
  3. Ping Cao

    Department of Chemistry, Stony Brook University, Stony Brook, United States
    Competing interests
    The authors declare that no competing interests exist.
  4. Zachary Ridgway

    Department of Chemistry, Stony Brook University, Stony Brook, United States
    Competing interests
    The authors declare that no competing interests exist.
  5. Jinghua Zhang

    Diabetes Research Program, Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, New York University School of Medicine, New York, United States
    Competing interests
    The authors declare that no competing interests exist.
  6. Ling-Hsien Tu

    Department of Chemistry, Stony Brook University, Stony Brook, United States
    Competing interests
    The authors declare that no competing interests exist.
  7. Chris T Middleton

    PhaseTech Spectroscopy, Inc., Madison, United States
    Competing interests
    The authors declare that no competing interests exist.
  8. Brian Chao

    Diabetes Research Program, Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, New York University School of Medicine, New York, United States
    Competing interests
    The authors declare that no competing interests exist.
  9. Daniel J Sartori

    Diabetes Research Program, Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, New York University School of Medicine, New York, United States
    Competing interests
    The authors declare that no competing interests exist.
  10. Fanling Meng

    Department of Chemistry, Stony Brook University, Stony Brook, United States
    Competing interests
    The authors declare that no competing interests exist.
  11. Hui Wang

    Department of Chemistry, Stony Brook University, Stony Brook, United States
    Competing interests
    The authors declare that no competing interests exist.
  12. Amy G Wong

    Department of Chemistry, Stony Brook University, Stony Brook, United States
    Competing interests
    The authors declare that no competing interests exist.
  13. Martin T Zanni

    Department of Chemistry, University of Wisconsin-Madison, Madison, United States
    Competing interests
    The authors declare that no competing interests exist.
  14. C Bruce Verchere

    Child & Family Research Institute and Department of Surgery and Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada
    Competing interests
    The authors declare that no competing interests exist.
  15. Daniel P Raleigh

    Department of Chemistry, Stony Brook University, Stony Brook, United States
    For correspondence
    Daniel.Raleigh@stonybrook.edu
    Competing interests
    The authors declare that no competing interests exist.
  16. Ann Marie Schmidt

    Diabetes Research Program, Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, New York University School of Medicine, New York, United States
    For correspondence
    annmarie.schmidt@nyumc.org
    Competing interests
    The authors declare that no competing interests exist.

Ethics

Animal experimentation: All procedures were approved by the Institutional Animal Care and Use Committee of New York University Langone Medical Center (NYULMC) and conform to the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH) (8th Edition, 2011, ISBN 10: 0-309-15400-6). The Animal Care and Use Program at NYULMC are in full compliance with NIH policy (NYULMC Compliance Number is A3435-01).

Copyright

© 2016, Abedini et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 4,274
    views
  • 946
    downloads
  • 136
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Andisheh Abedini
  2. Annette Plesner
  3. Ping Cao
  4. Zachary Ridgway
  5. Jinghua Zhang
  6. Ling-Hsien Tu
  7. Chris T Middleton
  8. Brian Chao
  9. Daniel J Sartori
  10. Fanling Meng
  11. Hui Wang
  12. Amy G Wong
  13. Martin T Zanni
  14. C Bruce Verchere
  15. Daniel P Raleigh
  16. Ann Marie Schmidt
(2016)
Time-resolved studies define the nature of toxic IAPP intermediates, providing insight for anti-amyloidosis therapeutics
eLife 5:e12977.
https://doi.org/10.7554/eLife.12977

Share this article

https://doi.org/10.7554/eLife.12977

Further reading

    1. Biochemistry and Chemical Biology
    2. Stem Cells and Regenerative Medicine
    Alejandro J Brenes, Eva Griesser ... Angus I Lamond
    Research Article

    Human induced pluripotent stem cells (hiPSCs) have great potential to be used as alternatives to embryonic stem cells (hESCs) in regenerative medicine and disease modelling. In this study, we characterise the proteomes of multiple hiPSC and hESC lines derived from independent donors and find that while they express a near-identical set of proteins, they show consistent quantitative differences in the abundance of a subset of proteins. hiPSCs have increased total protein content, while maintaining a comparable cell cycle profile to hESCs, with increased abundance of cytoplasmic and mitochondrial proteins required to sustain high growth rates, including nutrient transporters and metabolic proteins. Prominent changes detected in proteins involved in mitochondrial metabolism correlated with enhanced mitochondrial potential, shown using high-resolution respirometry. hiPSCs also produced higher levels of secreted proteins, including growth factors and proteins involved in the inhibition of the immune system. The data indicate that reprogramming of fibroblasts to hiPSCs produces important differences in cytoplasmic and mitochondrial proteins compared to hESCs, with consequences affecting growth and metabolism. This study improves our understanding of the molecular differences between hiPSCs and hESCs, with implications for potential risks and benefits for their use in future disease modelling and therapeutic applications.

    1. Biochemistry and Chemical Biology
    2. Structural Biology and Molecular Biophysics
    Jie Luo, Jeff Ranish
    Tools and Resources

    Dynamic conformational and structural changes in proteins and protein complexes play a central and ubiquitous role in the regulation of protein function, yet it is very challenging to study these changes, especially for large protein complexes, under physiological conditions. Here, we introduce a novel isobaric crosslinker, Qlinker, for studying conformational and structural changes in proteins and protein complexes using quantitative crosslinking mass spectrometry. Qlinkers are small and simple, amine-reactive molecules with an optimal extended distance of ~10 Å, which use MS2 reporter ions for relative quantification of Qlinker-modified peptides derived from different samples. We synthesized the 2-plex Q2linker and showed that the Q2linker can provide quantitative crosslinking data that pinpoints key conformational and structural changes in biosensors, binary and ternary complexes composed of the general transcription factors TBP, TFIIA, and TFIIB, and RNA polymerase II complexes.